Multi-Drug Resistance in Cancer: Mechanism and Treatment Strategies

ISBN-13: 9781394209217 / Angielski

Rishabha Malviya; Arun D. Singh; Deepika Yadav

Spis treści

Foreword xiiiPreface xvAcknowledgment xvii1 Multi- Drug Resistance in Cancer: Understanding of Treatment Strategies 1Rishabha Malviya, Arun Kumar Singh and Deepika Yadav1.1 Introduction 11.2 Both Congenital and Developed Resistance to Drugs 31.2.1 Intrinsic Resistance 31.2.2 Acquired Resistance 41.3 Drug- Resistance Mechanisms 61.3.1 Increased Efflux of Drugs 61.3.2 Impact on Medication Target 71.3.3 Improved DNA- Damage Repair 91.4 Senescence Escape 91.5 Epigenetic Alterations 91.6 Tumor Heterogeneity 101.7 Tumor Microenvironment 111.8 Epithelial to Mesenchymal Transition 131.9 Conclusion 15References 182 Understanding Different Mechanisms Involved in Cancer Drug Resistance: Proposing Novel Strategies to Overcome MDR 31Rishabha Malviya, Arun Kumar Singh and Deepika Yadav2.1 Introduction 312.2 Drug Resistance: Internal and External Variables 332.2.1 Phenotypic Variation of Tumors 332.2.2 Tumor Microenvironment 332.2.3 Cancer Stem Cells 332.2.4 Inactivation of the Anticancer Drugs 342.2.5 Multi-Drug Resistance 352.2.6 Increasing the Release of Drugs Outside the Cell 352.2.7 Reducing the Absorption of the Drugs 362.2.8 Inhibition of Cell Death (Apoptosis Pathway Blocking) 362.3 Improving the Pharmacokinetics 372.4 Changing the Aim of the Chemotherapy Agents 372.5 Improving the DNA Repair Process 392.5.1 Augmentation of a Gene 392.5.2 Epigenetic Altering Caused Drug Resistance 392.6 MicroRNA in Cancer Drug Resistance 402.7 Conclusion 41References 413 Molecular Mechanism of Multi-Drug Resistant Cancer Cells 47Rishabha Malviya, Arun Kumar Singh and Deepika Yadav3.1 Introduction 473.2 Types of Drug Resistance 483.3 Mechanisms of Drug Resistance 493.3.1 Drug Efflux via ABC Transporters 493.3.2 Permeability Glycoprotein/MDR- 1 513.3.3 Multi-Drug Resistance Protein 523.3.4 Breast Cancer Resistance Protein 533.4 Reduction in Drug Activity and Cellular Absorption 543.5 Instability in the Genome and Medication Resistance 563.5.1 Mutation and Medication Target Alteration 563.5.2 Restoration of DNA Integrity 573.5.3 Resistant Genes and Epigenetic Modifications 583.5.4 Drug Resistance and Programmed Cell Death 593.6 RNA Interference Therapy 623.7 Methods of Physical Intervention to Treat MDR 643.8 Conclusion 65References 664 Natural Products for Clinical Management of Drug Resistant Cancer Cells 77Rishabha Malviya, Arun Kumar Singh and Deepika Yadav4.1 Introduction 774.2 Resistance Mechanisms 784.3 Antitumor Plants for Multi-Drug- Resistant Cells 794.4 Qualea Species and Their Medical Applications 824.5 Antitumor Activity of Qualea Grandiflora and Qualea Multiflora 834.6 Conclusion 83References 845 Understanding of Autophagy to Combat MDR During Anticancer Therapy 87Rishabha Malviya, Arun Kumar Singh and Deepika Yadav5.1 Introduction 875.2 Mechanisms of Autophagy 895.2.1 Phagophore Assembly 895.2.2 Autophagosome Formation and Maturation 905.2.3 Autolysosome Degradation 905.2.4 Core Regulator of Autophagy 905.3 Mechanisms of MDR 915.4 Correlation Between Autophagy and Multi-Drug Resistance 925.5 The Cytoprotective Effect of Autophagy in the Regulation of Multi-Drug Resistance 935.6 Increased Autophagy Facilitates Multi-Drug Resistance 935.7 Autophagy Inhibition Improves Chemotherapy in MDR Cancers 955.8 Overcoming MDR With Autophagic Cell Death 965.9 Autophagy Kills Apoptosis- Deficient MDR Cancer Cells 975.10 Autophagy Promotes Chemosensitivity 975.11 Conclusion 98References 996 Transporter Inhibitors: A Chemotherapeutic Regimen to Improve the Clinical Outcome of Colorectal Cancer 105Rishabha Malviya, Arun Kumar Singh and Deepika Yadav6.1 Introduction 1066.2 CRC Transporters or ATP- Binding Cassette 1076.2.1 ABC Transporter Family 1076.2.2 ABC Transporters and CRC Initiation 1086.2.3 ABC Transporters and the Resistance of Cancer Cells to Chemotherapy 1096.3 Clinical Evidence for the Function of ABC Transporters in CRC MDR 1116.3.1 Intrinsic Drug Resistance in Colon Cancer Upregulation of P- gp at Detection 1116.3.2 Proliferating Tumor Cells Have MRP1 on Their Surface 1126.4 General Approaches 1136.5 By Blocking Tyrosine Kinase Inhibitors from Inhibiting MDR Transporters 1156.6 Components Produced from Natural Sources that Inhibit MDR Transporters 1166.7 Inhibiting ABC Transporters in Other Ways for CRC MDR Circumvention 1176.8 Challenges and Future Prospective 1186.9 Conclusion 119References 1197 Epithelial to Mesenchymal Transition (EMT): Major Contribution to Cancer Drug Therapy Resistance 131Rishabha Malviya, Arun Kumar Singh and Deepika Yadav7.1 Introduction 1317.2 EMT and Tumor Resistance: In Vitro, In Vivo, and Clinical Trials 1327.3 Tumor Microenvironment Regulates EMT 1367.3.1 Hypoxia 1387.3.2 The Extracellular Matrix 1397.3.3 The Inflammatory and Immune Microenvironment 1397.3.4 EMT Microenvironment: Medication Resistance 1407.4 Drug Resistance and EMT Bioinformatics 1427.4.1 Bioinformatics and Pharmacogenomics to Optimize Drugs and Targets and Identify Medication Resistance 1427.4.2 Drug Resistance: Hereditary or Acquired 1447.4.3 Therapies for EMT- Induced Medication Resistance 1447.5 Conclusion 145References 1468 Advances in Metallodrug- Driven Combination Therapy for Treatment of Cancer 155Rishabha Malviya, Arun Kumar Singh and Deepika Yadav8.1 Introduction 1568.2 Cancer Treatment Using Combination Therapy 1598.3 Combined Treatment with Metallodrugs for Cancer Treatment 1608.3.1 Platinum Metallodrugs 1618.4 Nonplatinum Metallodrugs 1648.5 Conclusion 166References 1679 Novel Strategies Preventing Emergence of MDR in Breast Cancer 171Rishabha Malviya, Arun Kumar Singh and Deepika Yadav9.1 Introduction 1719.2 Breast Cancer Categorization and Epidemiological Studies 1729.2.1 Treatment Options for Women With Breast Cancer 1739.3 Multi-Drug Resistance in Breast Cancer 1749.3.1 Breast Cancer Chemoresistance 1749.3.2 Multi-Drug Resistance and ABC Channels in Breast Cancer 1749.4 Drug Efflux Transporters in Breast Cancer 1759.4.1 Exocytosis Transporters in the Stem Cell Population of Breast Cancer 1759.4.2 Drug Efflux Channel Upregulation in Breast Cancer 1769.4.3 Techniques for Breast Cancer MDR Reversal 1779.4.4 Direct Pharmacologic Inhibition With MDR Inhibitors 1789.5 Excessive Synthesis or Overexpression of Transporters for the Expulsion of Drugs 1819.6 Nanotherapeutic Approach for MDR Reversal 1839.7 Breast Cancer's MDR Cure Problems and Future Outlook 1849.8 Conclusion 185References 186Index 195

O autorze

Rishabha Malviya, PhD, is an associate professor in the Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University. He has authored more than 150 research/review papers for national/international journals of repute and has been granted more than 10 patents from various countries while a further 40 patents are published/under evaluation. His areas of interest include formulation optimization, nanoformulation, targeted drug delivery, localized drug delivery, and characterization of natural polymers as pharmaceutical excipients.Arun Kumar Singh has completed M. Pharm (pharmaceutics) from Galgotias University, Greater Noida, India. His areas of interest are in the area of nanoformulation, blockchain, IoT, machine learning, cancer, artificial intelligence, and big data.Deepika Yadav completed M. Pharm from Galgotias University, Greater Noida, Uttar Pradesh. She has published several papers with reputed international publishers.